Hematologic Malignancy
Smoldering Multiple Myeloma
CI-CAN-00003983Explore in graph →
Hematologic34 active trials
- NCIt
- C7149
- MeSH
- D000075122
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003983Explore in graph →
Clinical trials
85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03839459 | Denosumab for Smoldering Multiple Myeloma | completed | Phase 2 | 20 | University of RochesterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01222286 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma(KIRMONO) | completed | Phase 2 | 30 | Innate PharmaINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT01237054 | Imaging in MGUS, SMM and MM | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2026 | clinicaltrials |
| NCT02916771 | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT00112827 | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | City of Hope Medical CenterOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT02903381 | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | completed | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02279394 | E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | completed | Phase 2 | 51 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT01302886 | Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma | completed | Phase 2 | 41 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT01441973 | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | completed | Phase 2 | 41 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01884688 | UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma | completed | Phase 2 | 3 | University of ArkansasOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00099047 | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 15, 2026source: clinicaltrials